The growing melanoma burden further supports the need for accessible and efficient skin-lesion assessment technologies. Recent US estimates show fluctuations followed by an upward trend in melanoma cases, reaching 212,200 cases in 2025, highlighting the increasing clinical need for early detection and ongoing lesion monitoring. The year-wise estimates are presented below. Estimated Melanoma Cases in US, 2022–2025 Year Total Melanoma Cases 2022 197,700 2023 186,680 2024 200,340 2025 212,200 Source: AIM at Melanoma Foundation US Melanoma Burden and Relevance to Digital Dermatoscopy Disease Indicator 2025 Estimate Relevance to Digital Dermatoscopy New melanoma cases 212,200 Expanding population requiring diagnosis and monitoring Noninvasive melanoma 107,240 Opportunity for early lesion identification Invasive melanoma 104,960 Supports need for timely assessment 5-year increase in invasive cases 16% Indicates continuing disease burden, driving future demand for diagnosis Regulatory Landscape The regulatory landscape demonstrates that digital dermatoscopy is no longer limited to conventional optical devices. In the US, for example, the FDA has cleared digital dermatoscopy products through the 510(k) pathway. June 2026:DermaSensor announced a Class IIb CE Mark for its AI and spectroscopy based handheld skin cancer detection device and disclosed a feasibility collaboration with the UK National Health Service to evaluate AI assisted skin-cancer assessment by GPs. The company also disclosed a strategic European distribution partnership, with the distributor investing USD 5 million in DermaSensor's Series B financing. September 2025: MetaOptima Technology secured support from Canada's INOVAIT Pilot Fund, backed by the Government of Canada's Strategic Innovation Fund, for OptimaScan, an AI-powered total-body photography system designed to identify suspicious skin lesions and integrate with DermEngine for 3D body mapping and longitudinal monitoring. August 2025:GHO Capital completed its acquisition of a majority stake in FotoFinder Systems, with EMZ Partners retaining a meaningful minority position; the transaction strengthened FotoFinder's investment base for expansion in digital dermoscopy, total body imaging, diagnostic software and AI-enabled skin cancer detection. The transaction closed on 27 August 2025. Product Launches October 2025:DermaSensor announced a Class IIb CE Mark for its AI- and spectroscopy-based handheld skin cancer detection device and disclosed a feasibility collaboration with the UK National Health Service to evaluate AI-assisted skin-cancer assessment by GPs. The company also disclosed a strategic European distribution partnership, with the distributor investing USD 5 million in DermaSensor's Series B financing. September 2025:Canfield Scientific received a U.S. patent grant for a facial imaging apparatus, with the patent issued on 16 September 2025; the development adds to Canfield's intellectual-property portfolio in standardized medical and skin imaging. August 2025:Affidea Group entered into a strategic partnership with Skin Analytics to deploy the DERM AI medical device software for automated skin lesion analysis, initially across clinics in Romania and Lithuania, with Greece planned for September, expanding AI supported skin cancer assessment across its European network. Technology Landscape Smartphone Compatible Systems Smartphone connected dermatoscopes allow the clinician to use the smartphone camera as part of the imaging workflow, reducing the need for a dedicated imaging workstation. DermLite's DL5 Plus model allows control of illumination modes and can capture multiple imaging modes through its MultiShot functionality without wireless connectivity. AI Digital Dermatoscopy AI is emerging as one of the most important technology developments in digital dermatoscopy. Instead of simply storing an image, AI enabled systems can potentially evaluate lesion characteristics, identify suspicious patterns, compare images over time, and assist clinicians with prioritization. A systematic review and meta analysis of deep learning algorithms using dermoscopic images reported a pooled sensitivity of 82%, specificity of 87%, and AUC of 0.92 for melanoma detection. Patent Landscape The intellectual-property landscape can broadly be divided into five technology areas: device and illumination architecture, digital image processing, lesion monitoring, AI-based image analysis, and multimodal imaging. Established players such as Canfield Scientific and DermLite have built patent portfolios around core dermoscopy hardware and imaging technologies, while newer developments increasingly focus on extracting additional clinical information from digital images. Patent Landscape for Dermatoscopes (As of 2026) Country No. of Patents Applicants No.of Patents China 8 BARCO NV 9 Australia 3 MAGNOSCO GMBH 4 European Patent Office 3 LIU YALI 2 US 3 AIGAO SENDE MEDICAL DEVICES (BEIJING) CO LTD 1 PCT 3 BEIJING DERMAT SPEEDY RECOVERY TANDD CO LTD 1 Canada 1 BEIJING INSTITUTE OF COLLABORATIVE INNOVATION 1 Spain 1 BEIJING RAYSHINE HEALTH TECH CO LTD 1 Thus, digital dermatoscopes are evolving from imaging devices into connected dermatology platforms, driven by smartphone integration, AI-assisted analysis, longitudinal monitoring, and multimodal imaging. Continued product innovation, regulatory progress, and software integration are expected to create new opportunities across clinical care, teledermatology, and early skin cancer detection. Share this article